ArticleAlimentary pharmacology & therapeutics2024

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.

Philip N Newsome et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.